InvestorsHub Logo
Followers 28
Posts 2529
Boards Moderated 0
Alias Born 05/08/2015

Re: theswordman post# 192539

Thursday, 11/04/2021 5:39:21 PM

Thursday, November 04, 2021 5:39:21 PM

Post# of 233150

The only fraud that's going on here is when Amarex billed CytoDyn $80m"--REALLY??


Yes, REALLY. This PR is from Amarex - not CytoDyn. And this isn't fraudulent on Amarex???

Let's see the failed 13D gang of miscreants spin this one (they'll probably tell us it was written by NP who showed up at their office with a gun and forced them to release this PR). Why do the 13D gang of miscreants continue to lurk around in the dark and spin their webs of deceit? I bet one of the disgruntled 13D gang members, Anthony Caracciolo, can answer that question, but you'll have to find his Florida hideout to ask him the question. I hear Tampa is a good place to start the search.

https://www.amarexcro.com/news/amarex-sumits-biologics-license-cytodyn

"Amarex Submits a Biologics License Application (BLA) on Behalf of its Client, CytoDyn, for a Product to Treat HIV Patients
Germantown, MD, USA (April 28, 2020) – Amarex Clinical Research, LLC, an NSF International company, announces today that they submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the product leronlimab (PRO 140), on behalf of their client, CytoDyn. The application was finalized with the submission of the clinical and CMC (chemistry, manufacturing and controls) sections of the BLA. The drug will be administered as a combined therapy in the treatment of HIV.

Amarex was involved in preparation of this BLA, providing biostatistics, medical writing and regulatory services. Kazem Kazempour, Ph.D., Co-Founder, President and Chief Executive Officer of Amarex said, “We have worked with our client CytoDyn for a number of years on PRO 140, and we are pleased to see that, after much hard work and dedication, we are moving towards marketing approval. Our clinical trials have been successful thus far, with PRO 140, and we hope to have the same result for ongoing trials of this drug in other indications."

My comments are just my opinions and should NOT be taken as investment advice.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News